Marinomed Biotech AG
MARI.VI · VIE
6/30/2025 | 3/31/2025 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | €0 | €0 | €0 | €0 |
| - Cash | €0 | €0 | €0 | €0 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €0 | €0 | €0 | €0 |
| Revenue | – | €0 | €0 | €0 |
| % Growth | – | 278.3% | 134.1% | – |
| Gross Profit | – | €0 | €0 | -€0 |
| % Margin | – | 0% | 39.9% | -204.4% |
| EBITDA | – | €0 | -€0 | -€0 |
| % Margin | – | 340.3% | -70.3% | -176.4% |
| Net Income | – | €0 | -€0 | -€0 |
| % Margin | – | 338.7% | -504.2% | -288.8% |
| EPS Diluted | – | 12.44 | -5.65 | -1.39 |
| % Growth | – | 320.2% | -306.5% | – |
| Operating Cash Flow | – | – | -€0 | -€0 |
| Capital Expenditures | – | – | €0 | €0 |
| Free Cash Flow | – | – | -€0 | -€0 |